Dermavant Presents Results of Tapinarof in Pivotal P-III PSOARING Program at the 29th EADV Virtual Congress

Shots:

• The pivotal P-III clinical program for tapinarof in adult with PsO consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980) PSOARING 3 (NCT04053387), an ongoing long-term safety study. Positive results of P-III studies were reported in Aug’2020
• Tapinarof previously met the 1EP in separate P-IIb trials for PsO & AD, both studies were published in JAAD. The company anticipates its NDA filling in 2021
• Tapinarof (qd) is a steroid-free, cosmetically elegant, TAMA topical cream being developed for the treatment of PsO and AD. To date, 2200+ subjects have enrolled in 18 clinical trials of tapinarof

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Dermavant